Home Blog Page 724

China takes solid steps to promote higher-quality economic development

By
Advertorial Desk
-

BEIJING, March 6, 2026 /PRNewswire/ — A report from People’s Daily:

Chinese President Xi Jinping on March 5 took part in a deliberation with his fellow deputies from the delegation of Jiangsu province at the fourth session of the 14th National People’s Congress (NPC) in Beijing.

During the deliberation, he stressed that developing new quality productive forces is crucial to driving high-quality development and enhancing economic competitiveness.

He laid out clear requirements on developing new quality productive forces, enhancing economic resilience, and advancing common prosperity for all to fulfill the development goals of the 15th Five-Year Plan period (2026-2030).

He urged major provincial economies such as Jiangsu to redouble efforts to gain experience in analyzing new situations and solving new problems. His remarks carry important guiding significance for advancing Chinese modernization.

Why is developing new quality productive forces so important?

Over the past year, the world has witnessed humanoid robots progress from tentative first steps to performing impressive “kung fu-like” movements. China now ranks among the global leaders in robotics research and application. At the same time, homegrown AI large models driving the global open-source ecosystem, while domestically produced new energy vehicles are becoming a common sight in everyday households. Technological innovation is reshaping industries across the board, generating new momentum for growth and transform the way people work and live.

During the 14th Five-Year Plan period (2021-2025), China’s economy has navigated one challenge after another, maintaining steady and positive momentum despite a complex domestic and international environment.

A key factor behind this resilience has been the country’s firm commitment to high-quality development and its efforts to foster new quality productive forces tailored to local conditions.

Data released during this year’s “two sessions” are encouraging. China’s value-added manufacturing output has ranked first in the world for 16 consecutive years. In 2025, the value-added output in high-tech manufacturing and equipment manufacturing grew by 9.4 percent and 9.2 percent respectively. China has also built the world’s largest and fastest-growing renewable energy system.

In recent years, the Chinese economy has weathered multiple headwinds while maintaining strong resilience and vitality. A key reason lies in its comprehensive industrial system. Developing new quality productive forces has become essential for building a modern industrial structure, sustaining high-quality development, and strengthening the economy’s ability to withstand external shocks.

Across the country, regional economies are exploring their own pathways for industrial upgrading. Jiangsu has delivered a strong performance by advancing intelligent upgrading, digital transformation, and network connectivity of its manufacturing sector, building an internationally competitive advanced manufacturing base.

Guangdong has accelerated the development of the Guangdong-Hong Kong-Macao Greater Bay Area as an international center for scientific and technological innovation, with the Shenzhen-Hong Kong-Guangzhou innovation cluster now ranking first globally.

Anhui in east China has surged to the top nationally in both automobile and new-energy vehicle production, with vehicle exports exceeding one million units — a result of the province leveraging its unique position at the intersection of multiple national strategies.

Today, China has firmly anchored the strategic task of developing new quality productive forces. Major provincial economies are taking on greater responsibilities, while regions across the country are leveraging their comparative advantages and pursuing their own strengths — climbing to higher levels and moving toward new frontiers of development.

CARsgen Therapeutics Announces 2025 Annual Results

By
Advertorial Desk
-

SHANGHAI, March 6, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results.

Business Highlights

  • Cash and cash equivalents were around RMB1,123 million as of December 31, 2025. Cash and cash equivalents at the end of 2026 are expected to be not less than RMB1,000 million. The net loss for the year ended December 31, 2025 was RMB103 million, representing a decrease of approximately 87% compared to the year ended December 31, 2024. In light of operational factors such as the changes in operating cash flow, we expect to have adequate cash into the 2030.
  • During 2025, CARsgen has received a total of 218 confirmed orders of zevor-cel from its commercialization partner Huadong Medicine. In December 2025, zevor-cel has been included in China’s Commercial Health Insurance Innovative Drug Catalogue (2025).
  • The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) and granted Priority Review for satri-cel. The results of satri-cel confirmatory Phase II trial in China have been simultaneously published in The Lancet and at the 2025 ASCO Annual Meeting.
  • Multiple allogeneic CAR-T products are in development, covering treatment areas such as hematologic malignancies, solid tumors, and autoimmune diseases.
  • CARsgen independently developed the lentiviral-based CARvivo™ platform for creating in vivo CAR T-cell products.
  • CARsgen entered into strategic cooperation agreements with a key platform enterprise in Jinshan District, Shanghai to establish an advanced commercial manufacturing base for CAR T-cell products.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, “2025 is a pivotal year for CARsgen Therapeutics. As we enter the phase of substantial value realization in commercialization, zevor-cel has demonstrated an excellent market performance. Meanwhile, satri-cel, the world’s first CAR-T candidate for solid tumors that has entered the NDA review process, is expected to be approved in the first half of 2026 and initiate commercialization. With its strong clinical value and broad market potential, it is poised to become the company’s next core growth driver. In 2025, the company has shifted its focus to the field of allogeneic CAR-T cell therapies. We believe that off-the-shelf cell therapies capable of large-scale production are crucial for serving a broad patient population and opening a new chapter for the industry. Leveraging our proprietary THANK-uCAR® and THANK-u Plus™ platforms, we are advancing multiple allogeneic CAR-T candidates, with encouraging preliminary clinical data demonstrating promising efficacy and a favorable safety profile. Additionally, we are also advancing in vivo CAR T-cell therapies based on our proprietary CARvivo™ platform. Looking ahead, we will continue to unite our efforts, move forward with determination, and execute our strategic plans with rigorous precision, bringing renewed hope to patients worldwide.”

Financial Highlights

CARsgen’s revenue was around RMB125.7 million for the year ended December 31, 2025 mainly from zevor-cel, autologous BCMA CAR T-cell product in which the primary revenue of zevor-cel was calculated on the basis of ex-works price, rather than on the basis of end-of-market prices. Our revenue is recognized upon completion of ex-works delivery of products. Due to the inherent time cycle of CAR-T manufacturing, there is a discrepancy between the number of orders obtained from Huadong Medicine and number of ex-works deliveries. CARsgen’s gross profit was around RMB80 million for the year ended December 31, 2025. In the commercialization stage, we are demonstrating a strong cost competitive advantage, which is mainly due to self-manufacture for plasmids and vectors with stable output and high yield per batch. Our net loss was around RMB103 million for the year ended December 31, 2025, representing a decrease of around RMB695 million from around RMB798 million for the year ended December 31, 2024.

Cash and cash equivalents were around RMB1,123 million as of December 31, 2025, representing a decrease of around RMB356 million from around RMB1,479 million as of December 31, 2024. The decrease was mainly due to research and development expenses, administrative expenses and investment of capital expenditure. Cash and cash equivalents at the end of 2026 are expected to be not less than RMB1,000 million. In light of operational factors such as the changes in operating cash flow, we expect to have adequate cash into the 2030.

CARsgen Pipeline
CARsgen Pipeline

Zevor-cel demonstrates rapids sales growth

Zevorcabtagene autoleucel (zevor-cel, R&D code: CT053) is an autologous fully human CAR T-cell product against B-cell maturation antigen (BCMA) approved by the NMPA of China for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent).

CARsgen entered into a collaboration agreement with Huadong Medicine (000963.SZ) for the commercialization of zevor-cel in mainland China. In terms of commercialization, Huadong Medicine has established a dedicated, professional, and comprehensive commercial team to promote the use of zevor-cel and has been utilizing China’s multi-layered insurance system to improve patient accessibility. During 2025, certification and regulatory filings for zevor-cel have been completed in more than 20 provinces or cities and we have received a total of 218 confirmed orders from Huadong Medicine. In December, 2025, zevor-cel was included in China’s Commercial Health Insurance Innovative Drug Catalogue (2025). We anticipate that growth of sales revenue of zevor-cel will further accelerate with continuous marketing activities and broader insurance coverage.

The updated long-term follow-up results of Phase I clinical trial of CT053 have been published in Blood Advances. The updated data of Phase II clinical trial, involving 102 patients with a median follow-up of 20 months, were published in Experimental Hematology & Oncology. Zevor-cel demonstrates manageable safety profile while eliciting deep and durable responses in R/R MM patients.

CARsgen entered into a collaboration with Dispatch Bio, to conduct a Phase I trial in China, planned to begin in 2026. The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch’s first-in class Flare platform – including DV-10, the company’s novel tumor-specific virus – and zevor-cel, in patients suffering from solid tumors.

Satri-cel is about to be commercialized in China

Satricabtagene autoleucel (satri-cel, R&D code: CT041) is an autologous humanized CAR T-cell product against Claudin18.2. In China, satri-cel was granted Breakthrough Therapy Designation (BTD) in March 2025 and Priority Review in May 2025 by the CDE. In June 2025, the CDE of NMPA of China has accepted the NDA for satri-cel for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. Satri-cel is the first CAR T-cell therapy for the treatment of solid tumors that has advanced to NDA stage worldwide. It is expected to be approved and start commercialization in the first half of 2026.

The results of satri-cel confirmatory Phase II trial (NCT04581473) in China have been published in The Lancet and were orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Satri-cel demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit with a manageable safety profile, compared to standard therapy.

The research results of the Phase Ib registrational clinical trial of satri-cel for PC adjuvant therapy in China (NCT05911217) has been presented as a poster session at European Society for Medical Oncology (ESMO) Congress in October 2025. The trial represents the world’s first proof-of-concept (POC) study exploring CAR T-cell therapy for the adjuvant treatment of solid tumors.

In addition, an investigator-initiated trial (IIT) for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786), and an IIT for satri-cel as a sequential therapy following first-line treatment in patients with advanced G/GEJA (NCT07179484) have been conducted in China.

Multiple allogeneic CAR-T product candidates in development

CARsgen has been advancing differentiated allogeneic CAR T-cell products utilizing the CARsgen’s proprietary THANK-uCAR® and THANK-u Plus™ platform. THANK-u Plus™ platform, as an enhanced version of THANK-uCAR®, was developed to address the potential impact of NKG2A expression levels on therapeutic efficacy of the allogeneic CAR T-cells.

CT0596 is a BCMA-targeting allogeneic CAR T-cell product candidate deploying our THANK-u Plus™ technology. The IITs are ongoing in China to evaluate the safety and efficacy of CT0596 for the treatment of R/R MM and PCL. Two IND applications for R/R MM and primary plasma cell leukemia (pPCL) separately were submitted to the NMPA in December 2025 and have been accepted. Phase Ib registration trials in China are planned to be initiated in 2026. Preliminary results of an IIT have been presented at the 67th ASH in December 2025.

CT1190B (KJ-C2219) is an allogeneic CAR T-cell product candidate targeting CD19/CD20 deploying our THANK-u Plus™ technology, for hematologic malignancies and autoimmune diseases. The IITs have been initiated for R/R B-NHL, and for systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), separately. It is expected to obtain IND approval from the NMPA for B-cell malignancies in 2026. Phase Ib registration study is planned to be initiated in 2026 in China.

In addition, multiple products against different targets are currently under development: KJ-C2320 against CD38 for acute myeloid leukemia (AML); KJ-C2526 against NKG2DL for AML, other malignancies and senescence; CT1390B against CLL1 for AML; KJ-C2527 against Claudin18.2 for gastric cancer.

On February 25, 2025, CARsgen has entered into the agreements with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise (Limited Partnership), to jointly invest in UCARsgen Biotech Limited.

In vivo CAR-T product candidates in development

Apart from CAR T-cell products manufactured via in vitro gene editing, CARsgen is also developing in vivo CAR T-cell products. CARsgen’s proprietary lentiviral-based CARvivo™ platform demonstrates excellent T cell transduction and targeting specificity. KJ-C2529 is an in vivo CAR T-cell product candidate against CD19/CD20 deploying our CARvivo™ platform for the treatment of B-cell lymphoma. An IIT is expected to be initiated in 2026 for the treatment of R/R B-NHL.

Expand CAR-T commercial manufacturing base

CARsgen is actively preparing for capacity expansion, enhancing the manufacturing capabilities for CAR T-cell therapies that meet international standards to support the commercialization of multiple products and strengthen its global competitiveness. On February 12, 2026, CARsgen, through its indirectly wholly-owned subsidiary CARsgen Diagnostics Co., Ltd., signed strategic cooperation agreements with Shanghai Jingong Enterprise Development Co., Ltd., which is a key platform enterprise in the Bay Area High-Tech Zone of Jinshan District, Shanghai. With a total investment amount not exceeding RMB370 million, CARsgen will establish an advanced commercial manufacturing base for CAR T-cell products in Jinshan District, Shanghai. No significant upfront capital expenditure is required from CARsgen, effectively preserving valuable cash flow for core research and development as well as market expansion. In addition, the repurchase mechanism ensures CARsgen can fully acquire asset control after long-term operation, maintaining production stability and enhancing the flexibility of asset layout.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

For more information, please visit https://www.carsgen.com/ 

Elong Power Holding Limited Announces 1 for 80 Share Consolidations

By
Advertorial Desk
-

BEIJING, March 6, 2026 /PRNewswire/ — Elong Power Holding Limited (NASDAQ: ELPW) (the “Company”), a provider of high power battery technologies for commercial and specialty alternative energy vehicles and energy storage systems, today announced a share consolidation of the Company’s issued and outstanding Class A ordinary shares and Class B ordinary shares at a ratio of 1 for 80 shares (the “Reverse Split”), which will take effect at the open of The Nasdaq Stock Market (“Nasdaq”) on March 10, 2026.

On January 6, 2026, the Company held an extraordinary general meeting of the shareholders, and the shareholders approved to implement share consolidations of the Company’s Class A ordinary shares and Class B ordinary shares at any one time or multiple times, at the exact consolidation ratio and effective time as the Board may determine from time to time in its absolute discretion, provided that the accumulative consolidation ratio for all such share consolidations shall not be more than 4000:1, and authorized the Board to implement such share consolidations at any time during a period of up to two years of the date of the meeting. On March 5, 2026, the board approved implementation of the Reverse Split at a ratio of 1 for 80 shares.

The objective of the Reverse Split is to enable the Company to maintain compliance with Nasdaq Listing Rule 5810(c)(3)(A)(iii), which requires issuers listed on Nasdaq to maintain a closing bid price of greater than $0.10.

Upon the open of trading on March 10, 2026, the Company’s Class A ordinary shares will begin trading on a Reverse Split-adjusted basis, under the same symbol “ELPW” but under a new CUSIP number, G3016G129.

As a result of the Reverse Split, each 80 Class A ordinary shares with a par value of $0.00016 will automatically combine and convert into one issued and outstanding Class A ordinary share with a par value of $0.0128. Each 80 Class B ordinary shares with a par value of $0.00016 will automatically combine and convert into one issued and outstanding Class B ordinary share with a par value of $0.0128. The Reverse Split will affect all shareholders uniformly and will not alter any shareholder’s percentage ownership interest in the Company, except for minimal changes that may result from the treatment of fractional shares. No action is required by shareholders holding their shares through a brokerage account.

No fractional shares will be issued to any shareholders in connection with the Reverse Split, and each shareholder will be entitled to receive one full Class A ordinary share or Class B ordinary share, as applicable, in the Company in lieu of the fractional share that would have resulted from the Reverse Split.

At the time the share consolidation is effective, the Company’s total issued and outstanding common shares will change from approximately 63 million to approximately 0.79 million. The Company’s authorized shares will be proportionally reduced.

About Elong Power Holding Limited

Elong Power Holding Limited, a Cayman Islands exempted company, is committed to the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. Elong Power is led by Ms. Xiaodan Liu, Elong Power’s Chairwoman and CEO.

Elong Power has a comprehensive product and technology system that includes battery cells, modules, system integration, and battery management system development, based on high-power lithium-ion batteries and battery system products for long-cycle energy storage devices. Elong Power offers advanced energy applications and full life cycle services. Its product portfolio includes products utilizing lithium manganese oxide and lithium iron phosphate, among others, to meet the needs of high-power applications and energy storage applications in various scenarios.

Forward‑Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Elong Power Holding Limited
ir@elongpower.com 

China sets GDP growth target for 2026, eyeing stronger results

By
Advertorial Desk
-

BEIJING, March 6, 2026 /PRNewswire/ — This is a report from China SCIO:

China has set an economic growth target of 4.5% to 5% for this year, while pledging to strive for better results as authorities aim to balance structural reforms, risk prevention, and long-term development goals.

The goals are outlined in this year’s government work report submitted Thursday to the national legislature for deliberation.

At a press briefing, Shen Danyang, director of the State Council Research Office, described the goal as a “two-part target”: maintaining growth within the 4.5-5% range while “striving for better in practice.” The approach, he said, reflects both ambition and prudence amid evolving domestic and international conditions.

According to Shen, who headed the report’s drafting team, the growth target allows room for economic restructuring, risk prevention, and further reforms, while remaining aligned with China’s long-term development vision.

China aims to raise per capita GDP to the average level of developed countries by 2035, a goal set at the fifth plenary session of the 19th Communist Party of China Central Committee. During the 14th Five-Year Plan period (2021-2025), the economy expanded at an average annual rate of 5.4%, providing a foundation for future growth.

Based on expert estimates, Shen said, China would need average annual growth exceeding 4.17% over the next decade to achieve the 2035 target of a per capita GDP of more than US$20,000, doubling the figure from 2020.

“The proposed target is consistent with China’s growth potential,” Shen said, noting that forecasts from international institutions, economists, and think tanks broadly align with the government’s expectations.

Employment considerations were also a key factor behind the target. Around 20 million people are expected to enter the labor market this year, and even after accounting for vacancies due to retirement and other factors, the country will still need to create about 12 million new jobs, said Chen Changsheng, a member of the government work report drafting team and deputy director of the State Council Research Office.

Based on the relationship between economic growth and job creation in recent years, Chen said growth of 4.5-5% would be necessary to support employment at that scale. 

Shen added that setting a range-based target, rather than a fixed number, allows flexibility in responding to uncertainties in the global environment. It also allows local governments to set development goals suited to their own conditions, while guiding policymakers to prioritize high-quality growth.

Despite an increasingly complex and volatile external environment, Shen expressed confidence in China’s economic resilience. He said the country continues to benefit from its strong underlying vitality, a continuously improving economic structure, and the rapid development of new quality productive forces.

China will continue implementing more proactive and effective macro policies and deepen reforms in key sectors this year, steps that are expected to further unlock growth potential.

“With these favorable conditions fully utilized, we believe it is entirely possible to achieve better results,” Shen said.

China sets GDP growth target for 2026, eyeing stronger results

http://english.scio.gov.cn/pressroom/2026-03/06/content_118366169.html

Huawei, Meralco, and SANXING Ningbo Launch Intelligent Distribution Solution and Lighthouse Initiative

By
Advertorial Desk
-

BARCELONA, SPAIN – Media OutReach Newswire – 6 March 2026 – During MWC2026, Huawei hosted a forum themed “Advancing All Intelligence, Empowering the Future Power System.” Together with Meralco (Philippines) and SANXING Ningbo, Huawei launched the Intelligent Distribution Solution (IDS) and announced a joint lighthouse initiative to advance power system development.

From left: Simon Zhou (General Manager of Overseas Marketing, SANXING Ningbo), David Sun (CEO, Huawei Electric Power Digitalization BU), Roque D. Bacani (Chief Information Officer, Meralco), and Perry Yang (Vice President, Huawei Optical Business Product Line) launching Huawei IDS
From left: Simon Zhou (General Manager of Overseas Marketing, SANXING Ningbo), David Sun (CEO, Huawei Electric Power Digitalization BU), Roque D. Bacani (Chief Information Officer, Meralco), and Perry Yang (Vice President, Huawei Optical Business Product Line) launching Huawei IDS

Communication, digitalization, and AI: Emerging cornerstones of future power systems that will accelerate the intelligent evolution of distribution networks

David Sun, CEO of Huawei’s Electric Power Digitalization BU, highlighted four drivers for energy transition: green energy and diversity, resilient grids, transparent distribution, and load electrification. He called for policy changes toward dispatch-market coordination. He also emphasized that communication, digitalization, and AI are becoming core production systems, requiring stronger capabilities in digital transformation, cybersecurity, and sustainable development.

At the forum, Mr. Sun unveiled the White Paper on Communication Target Networks for the Future Power System, introducing a pioneering architecture that features an intelligent and robust main network, integrated medium-voltage and transparent low-voltage networks, high-speed secure connectivity, and space-ground integration. The paper also outlines key tech trends, from optical and wireless to carrier and satellite communications, and underscores their transformative value.

Huawei highlighted its focus on intelligence and digitalization, working with industry players to drive power transformation. Global industry leaders also shared their insights: Al’Louise van Deventer (Technology and Engineering General Manager, Eskom) on future-ready digital practices; Momar Awa Sall (Transmission Grid Director, Senelec) on private wireless networks accelerating power modernization; Deniz COSKUN (Deputy General Manager, TEİAŞ) on restructuring communication networks for grid resilience; and Andy Liu (Overseas Solutions and Marketing Director, SANXING Ningbo) on the application of Huawei IDS.

Global industry leaders and partners join to explore the future of power systems

Power distribution networks are evolving from mechanized to automated and intelligent systems, driving technological and business model innovation. Despite creating new challenges for O&M, they have unlocked further opportunities for improving grid reliability and resource allocation.

At the forum, Huawei, Meralco, and SANXING Ningbo, unveiled the IDS that delivers four core capabilities—reliable communication, edge computing, cloud-edge collaboration, and low-voltage transparency—based on a cloud-pipe-edge-pipe-device architecture. It enables an intelligent low-voltage (400 V) distribution network with controllable line loss, visualized distribution rooms, and manageable renewables, transforming fragmented digital silos into open, integrated digital systems. The three companies also announced a lighthouse showcase initiative, sharing replicable and scalable digital transformation best practices.

Advancing digital and intelligent integration for a greener, more reliable grid

Communication, digitalization, and AI are at the heart of future power systems. Huawei will deepen R&D in digital, intelligent technologies, integrating advanced intelligence into power production. Together with global partners, Huawei is committed to developing with the power industry toward greater reliability, stronger security, and a low-carbon future.
Hashtag: #Huawei

The issuer is solely responsible for the content of this announcement.

Thailand Unveils Public–Private Alliance to Lead Asia’s Wellness Economy Revolution BDMS Wellness Clinic Rises as National Orchestrator of a Science-Powered, Luxury-Integrated Wellness Ecosystem

By
Advertorial Desk
-

BANGKOK, THAILAND – Media OutReach Newswire – 6 March 2026 – BDMS Wellness Clinic, the preventive healthcare center under Bangkok Dusit Medical Services Public Company Limited (BDMS), is spearheading a defining new chapter in Thailand’s national development strategy through strategic partnerships with public and private sectors both locally and internationally — including collaboration with the Global Wellness Institute (GWI), the preeminent global research and advisory organization dedicated to advancing the wellness economy, widely recognized for its data-driven industry intelligence, economic impact reports, and policy guidance shaping wellness markets worldwide. Together with global biotechnology pioneers including Illumina, Abbott, Straumann Group, and Gene Solutions, and further strengthened by distinguished GCC partners such as Neem Hospital and the MODAWI Platform, BDMS Wellness Clinic is forging a powerful bridge between Southeast Asia and the Middle East. Complemented by leading Thai institutions including National Healthcare Systems (N Health), Tourism Authority of Thailand (TAT), and Thailand Convention and Exhibition Bureau (TCEB), this alliance reflects an unprecedented convergence of science, policy, infrastructure, and international collaboration — reinforcing Thailand’s rise as Asia’s premier Wellness Economy hub.

Tanupol Virunhagarun, M.D., Chief Executive Officer of BDMS Wellness Clinic and BDMS Wellness Resort, Bangkok Dusit Medical Services Public Company Limited
Tanupol Virunhagarun, M.D., Chief Executive Officer of BDMS Wellness Clinic and BDMS Wellness Resort, Bangkok Dusit Medical Services Public Company Limited

A Multi-Sector Coalition at Unprecedented Scale

Led and orchestrated by BDMS Wellness Clinic, this alliance represents one of the most holistic cross-industry coalitions in Thailand’s health and tourism landscape. As the central integrator, BDMS Wellness Clinic unites public agencies, aviation leaders, hospitality icons, financial institutions, and global biotechnology innovators into a single, strategically aligned Wellness Ecosystem. Key national partners include the Thailand Convention and Exhibition Bureau (TCEB), Thailand Privilege Card Co., Ltd., and the Thai Spa Association, with regional connectivity strengthened by Bangkok Airways. The luxury and lifestyle dimension features Sri panwa Phuket, CELES SAMUI, Mövenpick BDMS Wellness Resort Bangkok, Dusit Thani Bangkok, King Power Corporation, Siam Piwat Co., Ltd., and Lancôme by L’Oréal Thailand.

Healthcare infrastructure and precision diagnostics are reinforced by National Healthcare Systems (N Health), enabling advanced laboratory networks, cross-border clinical data integration, and continuity of care. This capability is further elevated through collaboration with global medical and biotechnology leaders — Straumann Group in advanced dental innovation, Illumina in genomic sequencing, Abbott in precision diagnostics, and Gene Solutions in next-generation molecular testing.

Through this convergence of genomics, biomarker analytics, regenerative technology, and preventive medicine, BDMS Wellness Clinic delivers data-driven health optimization—from early disease detection and biological age assessment to personalized longevity programs. Together, under BDMS Wellness Clinic’s leadership, these partners form a fully integrated, science-powered ecosystem that transforms preventive care into measurable outcomes—firmly positioning Thailand at the forefront of Asia’s Wellness Economy.

From Healthcare Provider to National Orchestrator

BDMS Wellness Clinic has evolved beyond the traditional role of a healthcare provider to become the strategic integrator of Thailand’s Wellness Ecosystem—serving as the “National Orchestrator” uniting public institutions, private enterprises, academia, and global partners under one coordinated vision. Its mission extends far beyond treatment: to optimize healthspan, precise longevity science, and build a sustainable ecosystem where wellness becomes both a national economic engine and a form of diplomatic soft power. By synchronizing infrastructure, policy, aviation, hospitality, finance, and biotechnology, BDMS Wellness Clinic is repositioning Thailand from a destination known primarily for leisure and elective care into a global epicenter of evidence-based preventive medicine and measurable health optimization.

BDMS Wellness Clinic with Wellness Literacy: The Foundation of Sustainable Global Leadership

Sustainable global leadership demands more than world-class facilities—it requires a new generation of visionaries, scientists, and industry leaders equipped to redefine the future of health. BDMS Wellness Clinic has therefore launched a transformative Wellness Literacy strategy designed to cultivate world-class human capital, elevate professional standards, and shape a knowledge-driven ecosystem that positions Thailand at the forefront of preventive medicine and longevity science in Asia and beyond.

Through strategic alliances with leading institutions—including Thammasat University and King Mongkut’s Institute of Technology Ladkrabang (KMITL) in Thailand, as well as the University of Sharjah (UAE) and Singapore Management University (SMU)—BDMS Wellness Clinic is co-developing advanced curricula in preventive medicine, longevity science, and wellness management. These collaborations are establishing a new Asian benchmark for preventive healthcare education while producing a future-ready workforce for the global wellness economy. Beyond academia, BDMS Wellness Clinic is empowering entrepreneurs and industry operators nationwide, equipping hospitality, spa, and lifestyle businesses with measurable wellness standards—elevating Thailand’s entire value chain to international levels of excellence.

From Thailand to the World: BDMS Wellness Clinic’s Global Wellness Network

Extending its ecosystem beyond national borders, BDMS Wellness Clinic has forged strategic alliances with Neem Hospital—a leading private healthcare institution in the Sultanate of Oman known for its integrated clinical services and patient-centered care—and the MODAWI Platform, a digital health coordination platform that streamlines medical referrals, clinical data exchange, and cross-border care navigation.

Together, these partnerships establish a seamless referral and clinical integration network linking the GCC region with BDMS Wellness Clinic services. By combining hospital-based clinical excellence with digital health infrastructure, the model ensures continuity of care across borders—enabling patients to transition smoothly from initial consultation in the Middle East to advanced diagnostics, genomics, and longevity programs.

The Proof of Concept: “The Journey Within”

The flagship initiative, “The Journey Within,” translates vision into execution—serving as the living blueprint of the Wellness Ecosystem envisioned by BDMS Wellness Clinic. Anchored in three seamlessly integrated pillars—Travel, Stay, and Scientific Wellness—the concept redefines how a nation can deliver holistic, outcome-driven health experiences.

  • Travel: Luxury aviation partnerships, streamlined entry facilitation, and curated collaborations with lifestyle partners—ensuring effortless arrival and a seamless transition into an elevated wellness journey.
  • Stay: Curated luxury hospitality designed to immerse guests in restorative comfort and elevated living.
  • Scientific Wellness: Technological diagnostics, genomics, and precision-driven longevity programs delivering measurable health transformation.

For more information about The Journey Within, click https://bdmswellness.co/40LNk4v

Hashtag: #BDMSWellnessClinic #สุขภาพที่ดีเริ่มที่การป้องกัน #LiveLongerHealthierHappier #PreventiveMedicine #LifestyleMedicine #ScientificWellness #WellnessHubThailand




The issuer is solely responsible for the content of this announcement.

BDMS Wellness Clinic

BDMS Wellness Clinic, a pivotal entity within the Bangkok Dusit Medical Services (BDMS) network—Thailand’s leading operator of private hospitals—embodies a forward-thinking approach to healthcare, prioritizing prevention over cure. Specializing in early detection and prevention of diseases, our clinic offers a holistic suite of services, including advanced dental care and fertility treatments. Leveraging cutting-edge science and technology, BDMS Wellness Clinic not only anticipates future health challenges but also enhances the quality of life, marking its stature as Asia’s premier healthcare facility dedicated to elevating both mental and physical well-being.

For more details:

Facebook: Facebook.com/BDMSWellnessClinic
Instagram: @BDMSWellness

Media Inquiries: Media Inquiries: Please contact Marketing and Communication Department, BDMS Wellness Clinic Co. Ltd.

Chanokphat Pawangkanan 098-369-5963 Email: chanokphat.pa@bdmswellness.com

Sasiwimol Techawanto 092-807-5893 Email:

Aulumu Wins Two 2026 iF Design Awards, Showcasing Design-Led Innovation in Tech Accessories

By
Advertorial Desk
-

SHENZHEN, China, March 6, 2026 /PRNewswire/ — Technology lifestyle brand Aulumu has been honored with two 2026 iF Design Award recognitions, one of the most prestigious global awards for design excellence. The awards recognize the Aulumu Geometric Case for AirPods Pro and the Aulumu Mag Buckle Ultra-Thin Strap, underscoring the brand’s commitment to combining bold industrial aesthetics with functional innovation in everyday technology accessories.

Organized by iF International Forum Design GmbH, the iF Design Award has been a globally recognized symbol of design excellence since 1954. Each year, thousands of entries from companies worldwide are evaluated by an independent panel of international design experts based on criteria such as innovation, functionality, form, and sustainability.

Winning two awards in 2026 marks a significant milestone for Aulumu, highlighting the brand’s growing influence in the global consumer electronics accessories market.

Award-Winning Product: Aulumu Geometric Case for AirPods Pro

The Aulumu Geometric Case for AirPods Pro received recognition for its distinctive industrial design and advanced protective engineering.

Inspired by a diamond-cut geometric design philosophy, the case transforms a standard earbud accessory into a visually striking lifestyle product. Sculpted surfaces and a bold polyhedral form create a futuristic aesthetic while maintaining everyday usability.

Functionality is central to the design. The case incorporates a patented seamless metal locking mechanism that prevents the lid from accidentally opening, helping protect earbuds from falling out during daily use.

To further enhance durability, the case features a multi-layer protection structure, including a high-elastic internal buffer layer and a four-corner hollow shock-absorbing outer structure designed to improve drop resistance. Additional details, such as a recycled lanyard and refined CMF (Color, Material, Finish) craftsmanship, reflect Aulumu’s focus on both sustainability and premium design.

Award-Winning Product: Aulumu Mag Buckle Ultra-Thin Strap

Aulumu’s second award-winning design, the Mag Buckle Ultra-Thin Strap, was recognized for its minimalist aesthetic and innovative fastening system.

The ultra-thin strap delivers a lightweight and modern wearable experience while maintaining durability and comfort for daily use. At the core of the design is a magnetic quick-release buckle that allows users to adjust the strap once and then easily attach or remove it with a simple magnetic connection.

For added security, the strap incorporates a Velcro-based secondary fastening structure, ensuring both convenience and stability during everyday activities.

The product reflects Aulumu’s design philosophy: blending futuristic aesthetics, intuitive usability, and refined engineering into accessories that complement modern digital lifestyles.

About Aulumu

Founded in 2022, aulumu is a design brand focused on high-performance gear, drawing inspiration from the functional aesthetics of cyberpunk and the philosophical roots of ancient Greek thought. Since its inception, the brand has launched dozens of digital accessory products, secured multiple utility and invention patents, and received the 2025 Red Dot Design Award. Today, aulumu products serve hundreds of thousands of users across more than 20 countries and regions, positioning the brand as a growing presence in the global high-performance accessories market.

For more information, visit: https://aulumu.com/, or follow aulumu on Instagram: https://www.instagram.com/aulumu_official/

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

By
Advertorial Desk
-

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ — Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previously out-licensed to TaiGen Biotechnology (TaiGen*-KY, 4157), has achieved its first milestone. Recently, TaiGen has successfully completed the enrollment and dosing of the first subject in the Phase I clinical trial.

The prevalence of CKD is steadily rising in the Greater China region. Anemia is one of the most common complications of CKD, affecting more than one in seven patients. ISM4808 is a potential best-in-class oral HIF-PHD inhibitor discovered with the support of Insilico Medicine’s generative chemistry platform, Chemistry42. Compared to traditional Erythropoiesis-Stimulating Agents (ESAs), ISM4808 stimulates the production of endogenous erythropoietin (EPO) and improves iron utilization. Its advantages, offering multiple advantages including improved iron use efficiency, avoidance of intravenous injections, and a favorable safety profile, with the potential to overcome limitations of existing treatment.

In December 2025, Insilico and TaiGen entered into a licensing agreement for the program. Under the agreement, TaiGen obtained exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). Insilico Medicine is eligible to receive an upfront payment, development and sales-based milestone payments, as well as tiered royalties on net sales, with the total deal value reaching tens of millions of US dollars.

Since entering the collaboration, TaiGen has efficiently initiated preparations for the Phase I clinical trial of this program. The Phase I clinical study is a randomized, double-blind, placebo-controlled trial comprising both single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts, designed to evaluate the safety, tolerability, and pharmacokinetic profile of ISM4808 in healthy adults.

Kuo-Lung Huang, Chairman of TaiGen Biotechnology, said, “ISM4808 is an important milestone in TaiGen’s drug development strategy. Within 3 months of in-licensing the program, our team completed the challenging process from regulatory preparation to first-subject enrollment and dosing, demonstrating TaiGen’s clinical development expertise. There remains significant unmet medical need in the CKD anemia market. We look forward to providing patients with a safer and more convenient oral treatment option through this novel mechanism, and we will continue to accelerate clinical progress to advance into the next stage of development as soon as possible.”

Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine, said, “We are deeply impressed by our partner TaiGen, who achieved clinical enrollment in less than three months after in-licensing the program. This highly efficient translational model—’AI-enabled early discovery + professional clinical development’—greatly shortens the distance from concept to the clinic. We look forward to ISM4808 delivering strong outcomes in clinical trials and bringing a clinically differentiated new oral treatment option to the broader CKD anemia patient community. ISM4808 was initially discovered as a candidate drug targeting the PHD mechanism with the support of Chemistry42. Garutadustat, another drug candidate targeting the PHD discovered and optimized by Chemistry42, is being independently advanced by Insilico for the treatment of inflammatory bowel disease. The first patient dosing for its Phase II clinical trial was completed in January 2026.”

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, HKEX:3696.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

1...723724725...6,334Page 724 of 6,334